Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by GlycoMimetics, Inc.
< Previous
1
2
Next >
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
July 25, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
June 04, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
May 29, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
May 06, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
April 25, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
March 27, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
March 13, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
February 26, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 12, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
January 04, 2024
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
December 10, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
November 09, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
November 03, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
October 20, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
September 06, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
August 02, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
July 19, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
June 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
June 15, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
May 31, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
May 03, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
April 26, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
March 29, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
March 16, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference
March 01, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 16, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee
February 15, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
February 06, 2023
From
GlycoMimetics, Inc.
Via
Business Wire
Tickers
GLYC
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright